136 related articles for article (PubMed ID: 37495200)
1. Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis.
Elhence H; Dodge JL; Lee BP
Clin Gastroenterol Hepatol; 2024 Feb; 22(2):315-323.e17. PubMed ID: 37495200
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.
Zhang X; Wong GL; Yip TC; Tse YK; Liang LY; Hui VW; Lin H; Li GL; Lai JC; Chan HL; Wong VW
Hepatology; 2022 Aug; 76(2):469-482. PubMed ID: 34939204
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
[TBL] [Abstract][Full Text] [Related]
4. Renin-Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study.
Christiansen CF; Heide-Jørgensen U; Rasmussen TB; Bodilsen J; Søgaard OS; Maeng M; Vistisen ST; Schmidt M; Pottegård A; Lund LC; Reilev M; Hallas J; Johansen NB; Brun NC; Sørensen HT; Thomsen RW
J Am Heart Assoc; 2020 Oct; 9(19):e017297. PubMed ID: 32998607
[TBL] [Abstract][Full Text] [Related]
5. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
; Lawler PR; Derde LPG; van de Veerdonk FL; McVerry BJ; Huang DT; Berry LR; Lorenzi E; van Kimmenade R; Gommans F; Vaduganathan M; Leaf DE; Baron RM; Kim EY; Frankfurter C; Epelman S; Kwan Y; Grieve R; O'Neill S; Sadique Z; Puskarich M; Marshall JC; Higgins AM; Mouncey PR; Rowan KM; Al-Beidh F; Annane D; Arabi YM; Au C; Beane A; van Bentum-Puijk W; Bonten MJM; Bradbury CA; Brunkhorst FM; Burrell A; Buzgau A; Buxton M; Cecconi M; Cheng AC; Cove M; Detry MA; Estcourt LJ; Ezekowitz J; Fitzgerald M; Gattas D; Godoy LC; Goossens H; Haniffa R; Harrison DA; Hills T; Horvat CM; Ichihara N; Lamontagne F; Linstrum KM; McAuley DF; McGlothlin A; McGuinness SP; McQuilten Z; Murthy S; Nichol AD; Owen DRJ; Parke RL; Parker JC; Pollock KM; Reyes LF; Saito H; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Singh V; Turgeon AF; Turner AM; Zarychanski R; Green C; Lewis RJ; Angus DC; Berry S; Gordon AC; McArthur CJ; Webb SA
JAMA; 2023 Apr; 329(14):1183-1196. PubMed ID: 37039790
[TBL] [Abstract][Full Text] [Related]
6. Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors.
Eworuke E; Welch EC; Haug N; Horgan C; Lee HS; Zhao Y; Huang TY
J Am Coll Cardiol; 2023 Jan; 81(4):321-331. PubMed ID: 36697132
[TBL] [Abstract][Full Text] [Related]
7. Effect of Angiotensin II Inhibitors on Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices.
Converse MP; Sobhanian M; Taber DJ; Houston BA; Meadows HB; Uber WE
J Am Coll Cardiol; 2019 Apr; 73(14):1769-1778. PubMed ID: 30975293
[TBL] [Abstract][Full Text] [Related]
8. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin system blockers and 1-year mortality in patients with post-operative acute kidney injury.
Slagelse C; Gammelager H; Iversen LH; Liu KD; Sørensen HT; Christiansen CF
Acta Anaesthesiol Scand; 2020 Oct; 64(9):1262-1269. PubMed ID: 32557539
[TBL] [Abstract][Full Text] [Related]
10. Risk of Viral Infection in Patients Using Either Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Nationwide Population-based Propensity Score Matching Study.
Lin SY; Ju SW; Lin CL; Lin CC; Hsu WH; Chou CH; Chi CY; Hsu CY; Kao CH
Clin Infect Dis; 2020 Dec; 71(10):2695-2701. PubMed ID: 32504531
[TBL] [Abstract][Full Text] [Related]
11. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
Qiao Y; Shin JI; Chen TK; Inker LA; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
JAMA Intern Med; 2020 May; 180(5):718-726. PubMed ID: 32150237
[TBL] [Abstract][Full Text] [Related]
12. Preadmission use of renin-angiotensin blockers and rupture of abdominal aortic aneurysm: a nationwide, population-based study.
Wemmelund H; Høgh A; Hundborg HH; Johnsen SP; Lindholt JS
Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):141-50. PubMed ID: 26817783
[TBL] [Abstract][Full Text] [Related]
13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
14. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study.
Lim JH; Cho JH; Jeon Y; Kim JH; Lee GY; Jeon S; Noh HW; Lee YH; Lee J; Chang HH; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Kim SW
Sci Rep; 2020 Nov; 10(1):20250. PubMed ID: 33219294
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
[TBL] [Abstract][Full Text] [Related]
17. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.
Wu CK; Yang YH; Juang JJ; Wang YC; Tsai CT; Lai LP; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
Medicine (Baltimore); 2015 Jan; 94(3):e424. PubMed ID: 25621694
[TBL] [Abstract][Full Text] [Related]
18. Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Short-Term Mortality After Sepsis: A Population-Based Cohort Study.
Hsu WT; Galm BP; Schrank G; Hsu TC; Lee SH; Park JY; Lee CC
Hypertension; 2020 Feb; 75(2):483-491. PubMed ID: 31838905
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
[TBL] [Abstract][Full Text] [Related]
20. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
